Latest Heparin Stories

DUBLIN, April 11, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/428k4v/heparin_cas) has announced the addition of the "Heparin (CAS 9005-49-6) Market Research Report" [http://www.researchandmarkets.com/research/428k4v/heparin_cas ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Heparin (CAS 9005-49-6) Market Research Report presents comprehensive data on heparin markets globally and...

DUBLIN, March 22, 2013 /PRNewswire/ -- Research and Markets has announced the addition of the "Product Strategies for Non-Oral Hematology Drugs" [http://www.researchandmarkets.com/research/qg3f6l/product ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The administration of non-oral drugs for the treatment of blood disorders has evolved over the past ten years to include heparin analogs and recombinant...

BASKING RIDGE, N.J., Dec. 19, 2012 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced it has secured a landmark $51 million Series E financing. The round was led by new investor RusnanoMedInvest, a subsidiary of the state-run Russian investment firm RUSNANO, and included participation from another new, US-based investor, Baxter Healthcare's venture initiative, Baxter Ventures....

ALBANY, New York, November 21, 2012 /PRNewswire/ -- New Market Research Report Added in MarketResearchReports.Biz Reports Database Global Heparin Market 2011-2015 [http://www.marketresearchreports.biz/analysis/150138 ] TechNavio [http://www.marketresearchreports.biz/publisher/73 ]'s analysts forecast the Global Heparin market [http://www.marketresearchreports.biz/analysis/150138 ] to grow at a CAGR of 11.2 percent over the period 2011-2015. One of the key factors...

Protection of Global Heparin Supply Focus of International Meeting Rockville, Md (PRWEB) August 02, 2012 As part of its role in ongoing efforts to better safeguard the global supply of medicines, the U.S. Pharmacopeial Convention (USP) will co-host the “Fifth Workshop on the Characterization of Heparin Products” at its U.S. headquarters in Rockville, Md., August 14-15, 2012. Since 2008, USP’s workshop on heparin products has provided a forum for manufacturers, regulators and other...

Third round of improvements to blood thinner standard announced by USP To help further secure a safe supply of the widely–used blood thinner heparin, a third round of revisions to quality standards for the drug has been advanced by the U.S. Pharmacopeial Convention (USP). USP's Expert Panel on Unfractionated Heparin ended a two-day meeting on May 16th, 2012, and recommended finalization of the proposed changes. The revisions are scheduled to appear in the November–December 2012 issue...

For decades, the blood thinner heparin has been used to prevent and treat blood clots. Could it be just as effective in treating cancer? In an editorial published today in the New England Journal of Medicine, researchers from McMaster University and the University at Buffalo suggest conclusive answers to key questions on the benefits of low molecular weight heparin (LMWH) for cancer patients remain elusive - despite promising results from large studies. Co-authors of the editorial are...

The use of an injectable, clot-preventing drug known as Low Molecular Weight Heparin to treat patients with advanced cancer complicated by blood clots increased steadily between 2000 and 2007, according to a new study published in The Oncologist, funded by the National Cancer Institute and led by Kaiser Permanente Colorado. However, despite previous research indicating LMWH is the preferred first-line treatment for cancer patients experiencing blood clots, use of LMWH is low compared to...

DENVER, Feb. 14, 2012 /PRNewswire/ -- The use of an injectable, clot-preventing drug known as Low Molecular Weight Heparin to treat patients with advanced cancer complicated by blood clots increased steadily between 2000 and 2007, according to a new study published in The Oncologist, funded by the National Cancer Institute and led by Kaiser Permanente Colorado. However, despite previous research indicating LMWH is the preferred first-line treatment for cancer patients experiencing...

BEDFORD, Mass., Feb. 14, 2012 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced the release of their new HemosIL AcuStar HIT Assay Panel assay as a European CE IVD Mark product under the European Directive on in vitro Diagnostic Medical Devices. This fully automated panel includes HemosIL AcuStar HIT-IgG(PF4-H) and HemosIL AcuStar HIT-Ab(PF4-H) assays. (Logo: http://photos.prnewswire.com/prnh/20100803/NE44435LOGO) HemosIL AcuStar HIT assays are the first...